EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Long-term efficacy of 0.19 mg fluocinolone acetonide intravitreal implant in the management of macular edema secondary to branch retinal vein occlusion: A case report

Emma Fiddimore, Lewis Larkman, Tara Gaur, Mohanad Moustafa, Amit Gaur

Indian Journal of Ophthalmology - Case Reports · 2026-07 · 6 (3) · 774-776

DOI: 10.4103/ijo.ijo_3333_25 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Indian Journal of Ophthalmology - Case Reports, online erschienen am 24.07.2026. Verfasst von Emma Fiddimore und 4 weiteren Autor:innen. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Macular oedema secondary to Branch Retinal Vein Occlusion (BRVO) is a major cause of vision loss, typically managed with intravitreal anti-VEGF agents or the short-acting dexamethasone implant (Ozurdex®). This case report demonstrates the long-term efficacy of the sustained-release 0.19 mg fluocinolone acetonide intravitreal implant (Iluvien®), an agent licensed for Diabetic Macular Oedema (DMO), as an off-label treatment for chronic, refractory BRVO-related macular oedema. A 63-year-old male with BRVO and persistent macular oedema initially responded favorably to seven anti-VEGF injections over one year, but subsequently developed a refractory response and vision deterioration. Over the next eight years, the patient received 15 Ozurdex® implants, which provided intermittent control but required increasingly frequent applications and led to steroid-induced cataract and elevated intraocular pressure. The patient then received an off-label Iluvien® implant in September 2022. At the 3-year follow-up (October 2025), the patient maintained a stable visual acuity of 83 letters and a dry macula (central retinal thickness 253 microns, with no recurrence of fluid or need for further injections. There was no increase in intraocular pressure. This case illustrates the successful and durable management of chronic, refractory BRVO-related macular oedema over a three-year period using the Iluvien® implant. For patients with a poor or diminishing response to anti-VEGF therapy, Iluvien® may warrant earlier consideration as an off-label application to reduce treatment burden and prevent prolonged disease activity, provided close monitoring for corticosteroid complications is maintained

Zitieren

APA

Fiddimore, E., Larkman, L., Gaur, T., Moustafa, M., & Gaur, A. (2026). Long-term efficacy of 0.19 mg fluocinolone acetonide intravitreal implant in the management of macular edema secondary to branch retinal vein occlusion: A case report. Indian Journal of Ophthalmology - Case Reports, 6(3), 774-776. https://doi.org/10.4103/ijo.ijo_3333_25

Vancouver

Fiddimore E, Larkman L, Gaur T, Moustafa M, Gaur A. Long-term efficacy of 0.19 mg fluocinolone acetonide intravitreal implant in the management of macular edema secondary to branch retinal vein occlusion: A case report. Indian Journal of Ophthalmology - Case Reports. 2026;6(3):774-776. doi:10.4103/ijo.ijo_3333_25

BibTeX
@article{Fiddimore2026,
  author = {Fiddimore, Emma and Larkman, Lewis and Gaur, Tara and Moustafa, Mohanad and Gaur, Amit},
  title = {Long-term efficacy of 0.19 mg fluocinolone acetonide intravitreal implant in the management of macular edema secondary to branch retinal vein occlusion: A case report},
  journal = {Indian Journal of Ophthalmology - Case Reports},
  year = {2026},
  volume = {6},
  number = {3},
  pages = {774--776},
  doi = {10.4103/ijo.ijo_3333_25}
}
Kostenlos starten →